ENVALITH
UBE株式会社 logo

UBE Corporation

4208・Prime Market・Chemicals

Official website
UBE株式会社 logo
UBE Corporation4208

Business

UBE Corporation is a comprehensive chemicals and machinery group with a history spanning over 120 years. Centered on five core segments—Functional Products (Polyimide, Separation Membrane, Ceramics, Separator), High-Performance Urethane, Pharmaceuticals, Resins & Chemical Products (Nylon, Elastomer, C1 Chemicals), and Machinery (Die Casting Machines, Industrial Machinery)—the company operates under a global five-region structure spanning Japan, Asia, Europe, the Americas, and China. With 76 consolidated subsidiaries, it serves a broad customer base across industries including automotive, electronics, energy, and pharmaceuticals. In 2022, the company changed its trade name from Ube Industries to UBE, accelerating the transformation of its business portfolio toward becoming a specialty chemicals company.

Business Model

The company's core focus is the manufacturing and sale of high-value-added products through integrated production from raw materials to final products (e.g., the polyimide chain starting from BPDA), while also earning licensing income by providing manufacturing technology licenses for DMC, EMC, and other products to Chinese and other companies. In the Machinery segment, After-Sales Service secures stable, recurring revenue. The company is advancing a structural transformation aimed at stabilizing earnings and improving capital efficiency by withdrawing from commodity businesses highly dependent on market conditions (such as ammonia and caprolactam) and concentrating resources on specialty businesses.

Company Strengths

The company possesses an integrated polyimide chain, producing everything from the raw material BPDA to varnish, film, powder, and gas separation membranes. It also has a track record of licensing technology externally, including a license for two-layer flexible copper-clad laminate manufacturing technology to Panasonic Industry (2004) and a polyimide license to SUMaterials (2011). The company has 589 R&D staff (approximately 7% of total employees), and R&D expenses for the Functional Products segment totaled ¥2,306 million.

The company has entered into manufacturing technology license agreements for DMC (dimethyl carbonate) and EMC (ethyl methyl carbonate) with more than 20 Chinese companies, concluded successively since 2010. In North America, UBE C1 CHEMICALS AMERICA, INC. is constructing DMC and EMC plants, which represent the main use of the ¥40,432 million in capital expenditure for the Resins & Chemical Products segment in the current consolidated fiscal year. The company has built a unique model that develops its C1 chemical chain globally through both technology licensing and in-house manufacturing.

The company has established a five-region structure spanning Japan, Asia (Thailand, China), Europe (Spain, Italy, the UK, etc.), the Americas, and China. In addition to manufacturing bases such as UBE CORPORATION EUROPE S.A.U. (Spain), UBE Chemicals (Asia) (Thailand), and THAI SYNTHETIC RUBBERS (Thailand), the company significantly expanded its global manufacturing and R&D network in April 2025 by acquiring the Urethane Systems business (with development sites in the US, China, and Italy) from LANXESS.

ENVALITH's Perspective

In FY2026 (ending March 2026), net sales came to ¥462,343 million and operating profit to ¥18,941 million, falling short of the numerical targets despite being the first year of the mid-term management plan. The major specialty segments—Functional Products, Pharmaceuticals, Machinery, and High-Performance Urethane—all posted lower sales and profits, and the overall results were supported by the structural reform effects in Resins & Chemical Products (reduced depreciation following impairment and no periodic repairs) along with a sharp increase in equity-method income. Until autonomous profit expansion in the specialty businesses is confirmed, we view the credibility of achieving the mid-term plan as limited.

Following the April 2025 acquisition of the urethane systems business from LANXESS (¥80,748 million), interest-bearing debt increased by ¥27,636 million from the end of the previous fiscal year to ¥358,172 million. Cash outflow from investing activities swelled to ¥140,232 million, more than double the previous year's level, and cash and cash equivalents decreased sharply from ¥115,442 million to ¥52,583 million. Goodwill balance also surged to ¥32,247 million (versus ¥2,002 million in the previous fiscal year), putting the company at a juncture where early realization of acquisition synergies and maintenance of financial soundness are being tested.

The structural reform is progressing steadily, with the caprolactam and nylon polymer manufacturing facilities in Thailand to be halted and scaled down in March 2026, followed by the halt of operations in Japan in March 2027 and the ammonia business in March 2028. On the other hand, the earnings forecast for FY2027 (ending March 2027) projects ordinary profit of ¥37,500 million, flat versus the previous fiscal year, as the disappearance of the ¥4,307 million foreign exchange gain recorded in the current fiscal year is expected to be a drag on ordinary profit. The impact of foreign exchange and raw material market fluctuations on performance remains significant as an external factor, and expanding the profit contribution from the specialty businesses remains essential.

Growth Strategy

Promoting transformation into a specialty chemicals company and improving capital efficiency through ROIC-based management

In April 2025, the company acquired the urethane systems business of 11 companies from LANXESS for ¥80,748 million, gaining a global manufacturing and sales structure for prepolymers used in thermosetting urethane elastomers, among others. Leveraging its strength in high-end applications such as semiconductor manufacturing equipment, the company is pursuing synergies with its existing PCD and PUD businesses. For FY2027 (ending March 2027), the High-Performance Urethane segment is forecast to achieve net sales of ¥68,000 million (up 46.1% year on year) and operating profit of ¥1,000 million (turning profitable).

The company is gradually withdrawing from the Ammonia, Caprolactam, and Nylon Polymer businesses, which have large earnings volatility and low profitability. Caprolactam and Nylon Polymer manufacturing facilities in Thailand were already halted or scaled down in March 2026. Caprolactam and Nylon Polymer manufacturing facilities in Japan are scheduled to be halted in March 2027, and Ammonia manufacturing facilities in March 2028. The company aims to stabilize its earnings structure by reducing depreciation expenses and curbing earnings volatility.

The company is continuing to invest in manufacturing facilities for polyimide film, separation membranes, ceramics, DMC, EMC, and other products. A new DMC/EMC plant is under construction in Louisiana, North America. For FY2027 (ending March 2027), the Functional Products segment is forecast to achieve net sales of ¥89,000 million (up 25.4% year on year) and operating profit of ¥15,000 million (up 52.1% year on year), reflecting the sales expansion effect from new facilities. From FY2027 (ending March 2027), UBE America Inc. will be incorporated into the Functional Products segment.

The company aims for net sales of ¥550,000 million, operating profit of ¥60,000 million, and ROE of 9% in fiscal year 2030, and net sales of ¥1 trillion, operating profit of ¥100,000 million, and ROE of 10% or more in fiscal years 2035 to 2040. The company is promoting optimization of capital allocation through ROIC-based management. In FY2026 (ending March 2026), the first year of the medium-term plan, the numerical targets were not achieved. The forecast for FY2027 (ending March 2027) calls for net sales of ¥485,000 million and operating profit of ¥23,500 million, representing an increase in both revenue and profit, but the gap from the fiscal year 2030 targets remains large.

Last updated: July 19, 2026